Yahoo Web Search

Sign In

Search results

  1. lyciatx.comHome - Lycia Therapeutics

    Lycia Therapeutics Founder Dr. Carolyn Bertozzi Awarded 2022 Nobel Prize in Chemistry. Read More. Read All News. 400 East Jamie Court, Suite 200. South San Francisco, CA 94080. info@lyciatx.com. © 2024 Lycia Therapeutics. About Us. LYTAC Platform.

    • About Us

      About Us - Lycia Therapeutics. Our Investors. “Lycia’s focus...

    • News

      Lycia Therapeutics Announces $70 Million Series B Financing...

    • LYTAC Platform

      Our LYTAC platform is designed to enable the depletion of...

  2. lyciatx.com › about-usAbout Us - Lycia Therapeutics

    About Us - Lycia Therapeutics. Our Investors. “Lycia’s focus on the untapped extracellular proteome and the potential to leverage the LYTAC platform across therapeutic modalities, including small molecules and antibodies, has the potential to transform the protein degradation field.” Clare Ozawa, Ph.D.

  3. lyciatx.com › lytac-platformPlatform & Applications - Lycia Therapeutics

    Our LYTAC platform is designed to enable the depletion of (versus the inhibition of) of many targets previously considered undruggable, and the development of novel therapeutics for currently underserved patient populations.

  4. investor.lilly.com › news-releases › news-releaseLilly and Lycia Therapeutics Enter into Strategic ...

    Aug 25, 2021 · Lycia Therapeutics, Inc. is a biotechnology company using its proprietary lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases, including cancers and autoimmune conditions.

  5. www.prnewswire.com › news-releases › lilly-and-lyciaLilly and Lycia Therapeutics Enter into Strategic ...

    Aug 25, 2021 · INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration...

  6. finance.yahoo.com › news › lycia-therapeuticsLycia Therapeutics Completes $106.6 Million Series C ...

    May 13, 2024 · SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the completion of an oversubscribed $106.6...

  7. People also ask

  8. www.linkedin.com › company › lycia-therapeuticsLycia Therapeutics | LinkedIn

    Lycia Therapeutics | 4,089 followers on LinkedIn. Building the leading extracellular protein degradation company | Lycia is a Series B biotech company building upon the novel platform...